J. Bonafous

123I-N-(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging

A. Veyre, N. Moins, J. Papon, 2002, European Journal of Nuclear Medicine and Molecular Imaging.

Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma.

J. Boire, A. Veyre, J. Papon, 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Early detection and monitoring of cartilage alteration in the experimental meniscectomised guinea pig model of osteoarthritis by 99mTc-NTP 15-5 scintigraphy

L. Sarry, N. Moins, J. Madelmont, 2007, European Journal of Nuclear Medicine and Molecular Imaging.

Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide).

A. Veyre, J. Madelmont, P. Souteyrand, 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Joint scintigraphy in rabbits with 99mtc-N-[3-(triethylammonio)propyl]-15ane-N5, a new radiodiagnostic agent for articular cartilage imaging.

A. Veyre, M. D. De Latour, J. Madelmont, 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Study of implanted biomaterial functionality by diphosphonate molecules labeled with radioactive99mTc

J. Madelmont, P. Labarre, J. Bonafous, 2007, Biological Trace Element Research.

Clinical study of [123I] N-(2-diethylaminoethyl)-4-iodobenzamide in the diagnosis of primary and metastatic ocular melanoma.

A. Veyre, M. Moreau, J. Bonafous, 1998, Acta ophthalmologica.

[Phase 2 clinical study of 123I-N-(2-diethylaminoethyl)-2-iodobenzamide in the diagnostic of primary and metastatic ocular melanoma].

A. Veyre, N. Moins, M. D’Incan, 2004, Journal francais d'ophtalmologie.